GSK620: an oral in vivo BD2 domain selective BET inhibitor
GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)
Merck hArg1 inhibitor
Merck hArg1 inhibitor (Merck oral in vivo human arginase 1 inhibitor) DHMOTM2020-03-04
Merck IDO1 inhibitor
Merck IDO1 inhibitor (Merck heme-displacing oral IDO1 inhibitor)
Constellation EZH2 inhibitor
Constellation EZH2 inhibitor (Constellation oral in vivo long-residence time EZH2 inhibitor)
Arcus CD73 inhibitor
Arcus CD73 inhibitor (Arcus non-nucleoside CD73 inhibitor)
MK-6884: M4 Positive Allosteric Modulator PET Tracer
MK-6884 (Merck M4 positive allosteric modulator PET tracer) 2022 Update: Human Ph. I data disclosed in https://doi.org/10.1126/scitranslmed.abg3684
sulfopin: A selective covalent Pin1 inhibitor
Sulfopin (Weizmann/Harvard selective covalent Pin1 inhibitor)
M3814: oral DNA-PK selective kinase inhibitor
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
Remibrutinib: An oral BTK-selective covalent kinase inhibitor
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
LMB763: A selective FXR partial agonist
LMB763 (nidufexor) (Novartis (GNF) oral in vivo selective FXR partial agonist)
ABBV-744: An oral in vivo BD2 domain selective BET inhibitor
ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)
AG-881: An oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate
AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)
FT-2102 (olutasidenib)
FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)
GS-9876 (lanraplenib)
GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)
Compound 25: A mutant KRASG12C allosteric covalent inhibitor
KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)
Compound 25: A RORγt oral in vivo allosteric inhibitor
RORγt inhibitor from Merck (Merck ROR-gamma-t oral in vivo allosteric inhibitor)
WF-47-JS03: An oral in vivo RET kinase inhibitor
(Novartis (GNF) oral in vivo RET kinase inhibitor)
BMS-986260: An oral in vivo selective TGF-beta-R1 kinase inhibitor
BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)